| 摘要: |
| 在银屑病的发病过程中, 约1/4的患者会并发银屑病型关节炎的临床表现, 如果能有一种药物可以同时作用于银屑病皮肤和关节, 那么无疑对患者是有益的。目前新兴的生物药物包括:肿瘤坏死因子抑制剂, 如阿达木单抗、伊那西普、英夫利昔单抗、戈利木单抗和赛妥珠单抗;抗IL-12/IL-23 p40药物, 如乌司奴单抗;抗IL-17药物, 包括苏金单抗、brodalumab。它们都对银屑病和银屑病型关节炎有良好的临床疗效和安全性。最近, 另有一些小分子化学物质应运而生, 如磷酸二酯酶4抑制剂阿瑞米拉和JAK抑制剂托法替尼、INCB018424等, 它们都有一定的治疗意义。本文就能够同时治疗银屑病、银屑病型关节炎的生物及小分子药物作一综述。 |
| 关键词: 银屑病 银屑病型关节炎 发病机制 生物药物 小分子药物 |
| DOI：10.3724/SP.J.1008.2015.00542 |
| 投稿时间：2014-09-29修订日期：2014-11-24 |
| 基金项目: |
|
| Biologic and small molecular agents for simultaneous treatment of psoriasis and psoriatic arthritis: research progress |
| LOU Ying,WANG Xu-guo,HU Jin-hong* |
(Department of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
*Corresponding author) |
| Abstract: |
| A quarter of the psoriasis patients develop psoriatic arthritis, and it would be beneficial if a preparation which can be used to treat the skin and joint symptoms at the same time. Currently these biologic agents could serve both include tumor necrosis factor inhibitors such as adalimumab, etanercept, infliximab, golimumab and certolizumab; anti-IL-12/IL-23 p40 antibodies such as ustekinumab; and anti-IL-17 agents such as secukinumab, brodalumab. Recently another group of small molecule agents has been found for the purpose: phosphodiesterase-4 inhibitor, apremilast, JAK inhibitor, tofacitinib and INCB018424. This review provides an overview on the agents that can be used for the concurrent treatment of skin and joint psoriasis. |
| Key words: psoriasis psoriatic arthritis pathogenesis biologic agents small molecule agents |
